A capital raise of $0.84 million (before costs) demonstrates growing confidence in the Felix sperm separation device, according to ASX-listed reproductive biotechnology company Memphasys. According to a statement from the company on Monday, it has successfully completed a share placement for that amount, with an additional non-renounceable rights issue to eligible shareholders potentially raising up…
The Australian Government announced on Monday it would invest $12 million to develop new Australian-made medical devices and medicine for people with cardiovascular disease and diabetes. Fourteen Australian start-up and innovator companies will receive funding and commercialisation support to develop improved treatment for management of cardiovascular disease and complications of type 1 and 2 diabetes.…
The National Reconstruction Fund Corporation will reportedly announce a $27 million stake in PolyActiva, a company commercialising an injectable device to treat glaucoma. According to The Australian Financial Review, the investment to be announced on Friday is alongside $13 million in new funding from Brandon Capital, and will support PolyActiva in moving to phase-two trials,…
Following news last week that it has begun appointing distributors for Remplir in the United States, Orthocell has announced clearance to begin selling the nerve repair product in Canada, a market it estimates to be worth $US 75 million. In an ASX statement on Wednesday, Orthocell said it has received a Medical Device Licence (MDL)…
A new startup aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM), according to a statement released on Tuesday. Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed by…
Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to its product development and strategy team. In a statement on Thursday morning (Australian time), the company said Dr Emilio Emini, Dr Nathalie Garcon, and Professor Paul Young will join Vaxxas as consultants to provide regulatory…
The Coalition for Epidemic Preparedness Innovations (CEPI) has approved progression of a $US 4.8 million ($7.2 million) program involving Vaxxas — a Brisbane-based, clinical-stage company developing a needle vaccine delivery platform — and an mRNA Japanese encephalitis vaccine (JEV) from SK bioscience. According to a statement from Vaxxas on Thursday, the program is to develop…
The University of Queensland-based Food and Beverage Accelerator (FaBA) has released a report on what it says is a “transformative opportunity” offered by precision fermentation. In a statement on Monday, UQ said that while fermentation itself is nothing new, its more recent version of the technique was “on the brink of producing tailored, sustainable food…
A new, locally-developed bioprinter has received positive feedback from institutes including the Peter MacCallum Cancer Centre and Harvard Medical School, according to University of Melbourne, and offers cancer researchers a new tool for replicating specific organs and tissues. In a statement from the university on Friday, it was claimed that the new 3D printer is…
An expansion to the Medicines Manufacturing Innovation Centre (MMIC) at Monash University has been officially opened, with a project through the centre also awarded funding to develop a new therapeutic agent. The MMIC will help medicines manufacturers invest in R&D and develop new products and skills, according to the Victorian government, which backed the centre…